Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429312 · ClinicalTrials.gov registry record · Phase 1
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
A Phase 1 study, sponsored by Jennerex Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00429312 is a Phase 1 study that has completed, run by Jennerex Biotherapeutics. The registered enrollment target is 10 participants.
The verdict
NCT00429312, a Phase 1 study, has completed, sponsored by Jennerex Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
Interventions
- BIOLOGICAL JX-594
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00429312
The ClinicalTrials.gov registry entry for NCT00429312 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jennerex Biotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JX-594 is the first listed.
NCT00429312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00429312 about?
NCT00429312 is a clinical study titled "A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma". The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
What is the current status of trial NCT00429312?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2007-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00429312?
The interventions under investigation include: JX-594 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00429312?
This trial is sponsored by Jennerex Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.